Dr. Sherman on the Role of Regorafenib in Liver Cancer

Morris Sherman, MD
Published: Friday, Jan 13, 2017



Morris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the emergence of regorafenib (Stivarga) and how it fits into the treatment of hepatocellular carcinoma (HCC).

Sherman believes that regorafenib should be the standard second-line treatment after sorafenib (Nexavar). Currently, second-line treatments include chemoembolization, which is used beyond what is known to be effective, as it can cause liver disease deterioration, says Sherman.

One of the challenges in determining where regorafenib fits into HCC treatment is patient selection, as there are no data to determine which subset of patients will respond well to the drug, and this trial is still in its early stages.
 
SELECTED
LANGUAGE


Morris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the emergence of regorafenib (Stivarga) and how it fits into the treatment of hepatocellular carcinoma (HCC).

Sherman believes that regorafenib should be the standard second-line treatment after sorafenib (Nexavar). Currently, second-line treatments include chemoembolization, which is used beyond what is known to be effective, as it can cause liver disease deterioration, says Sherman.

One of the challenges in determining where regorafenib fits into HCC treatment is patient selection, as there are no data to determine which subset of patients will respond well to the drug, and this trial is still in its early stages.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x